截至2026年1月22日收盘，建投能源（000600）报收于8.82元，较前一交易日下跌1.12%，最新总市值为 159.05亿元。该股当日开盘8.98元，最高9.0元，最低8.75元，成交额达3.3亿元，换手率为3.43%。 最新公告列表 《关于向专业投资者公开发行公司债券获得中国证监会注册批复的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司近日发布公告称，河北建投能源投资股份有限公司于2026年1月21日收到中国证监会《关于同意河 北建投能源投资股份有限公司向专业投资者公开发行公司债券注册的批复》（证监许可〔2026〕91 号）。批复同意公司向专业投资者公开发行面值总额不超过30亿元的公司债券。本次发行应严格按照报 送深圳证券交易所的募集说明书进行。批复自同意注册之日起24个月内有效，公司可在注册有效期内分 期发行公司债券。期间如发生重大事项，需及时报告并按规定处理。公司将在股东大会授权下择机办理 发行事宜，并履行信息披露义务。 ...

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

建投能源公告，公司于2026年1月21日收到中国证监会《关于同意河北建投能源投资股份有限公司向专 业投资者公开发行公司债券注册的批复》。根据批复，同意公司向专业投资者公开发行面值总额不超过 30亿元公司债券的注册申请。本次发行公司债券应严格按照报送深圳证券交易所的募集说明书进行。批 复自同意注册之日起24个月内有效，公司在注册有效期内可以分期发行公司债券。 ...

| 证券代码：000600 | 证券简称：建投能源 | 公告编号：2026-07 | | --- | --- | --- | | 证券代码：149516 | 证券简称：21建能01 | | | 证券代码：149743 | 证券简称：21建能02 | | 公司将按照有关法律法规和上述批复文件的要求，依据公司股东大 会的授权，择机办理本次公司债券发行的相关事宜，并及时履行信息披 露义务。 特此公告。 1 河北建投能源投资股份有限公司 关于向专业投资者公开发行公司债券 获得中国证监会注册批复的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 河北建投能源投资股份有限公司（以下简称"公司"）于 2026 年 1 月 21 日收到中国证券监督管理委员会《关于同意河北建投能源投资股份 有限公司向专业投资者公开发行公司债券注册的批复》（证监许可〔2026〕 91 号），批复内容如下： 一、同意公司向专业投资者公开发行面值总额不超过 30 亿元公司债 券的注册申请。 二、本次发行公司债券应严格按照报送深圳证券交易所的募集说明 书进行。 三、本批复自同意注册之日起 24 个月 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the stock will outperform the market by more than 15% over the next 12 months [6]. Core Insights - The company achieved a significant increase in net profit, reaching 1.9 billion RMB, which represents a year-on-year growth of 253%, exceeding expectations. The fourth quarter performance was particularly strong, driven by improved profitability in thermal power and a reduction in financial costs [6][9]. - The company completed a total electricity generation of 48.6 billion kWh in 2025, with a focus on increasing installed capacity through new thermal power projects. The expected increase in installed capacity is projected to contribute positively to profits [6][9]. - A market value management plan has been implemented, emphasizing shareholder returns through cash dividends. The company has maintained a consistent dividend policy over the past decade, with a notable dividend payout of 180 million RMB in the third quarter of 2025 [6][9]. - Profit forecasts for the company indicate net profits of 1.877 billion RMB, 1.818 billion RMB, and 1.948 billion RMB for 2025, 2026, and 2027, respectively. The latest closing price corresponds to a price-to-book (PB) ratio of 1.4, 1.2, and 1.1 for the respective years [6][9]. Financial Summary - Revenue for 2023 is projected at 18.946 billion RMB, with a growth rate of 3.5%. For 2024, revenue is expected to rise to 23.517 billion RMB, reflecting a growth rate of 24.1% [2][9]. - EBITDA is forecasted to increase significantly from 1.922 billion RMB in 2023 to 5.943 billion RMB in 2025, indicating strong operational performance [2][9]. - The company's return on equity (ROE) is expected to improve from 1.7% in 2023 to 16.0% in 2025, showcasing enhanced profitability [2][9]. - The company’s debt-to-asset ratio is projected to decrease from 67.5% in 2023 to 59.0% in 2025, indicating improved financial stability [2][9].

建投能源 20260121 摘要 建投能源 2025 年发电量同比下降 3.56%，主要受用电需求减少、新能 源挤压及采暖季温暖影响。公司全年归母净利润 18.77 亿元，同比增长 253.38%，每股收益约 1.04 元，尽管四季度煤价上涨影响盈利，但整 体经营态势良好。 公司煤炭采购主要依赖现货市场，灵活调整长协和现货比例以控制成本。 2025 年长协煤占比约 50%，未来将以长协为核心，根据市场需求调整 结构配比，确保价格和质量优势。 河北南网火电长协议价因煤价下降有所降低，但仍保持在标杆电价上浮 15%-16%左右。容量电价政策（165 元/千瓦·月）预计增加度电收入约 4 分 2 厘，对公司收入有显著补充。 公司火电脱硫参与现货交易比例不到 10%，预计未来变化不大。辅助服 务收入虽逐年增长，但占总营收比例仍较低，主要来源于河北省辅助服 务规则，与现货市场关联性不大。 在建火电项目包括西柏坡四期和任丘热电二期，预计 2026 年投产。参 股国能控股多个新增项目，秦皇岛发电一台机组已试运行，定州和沧东 项目时间节点相近，恒丰电厂二期尚未开工。 Q&A 请简要回顾建投能源 2025 年的经营概况。 20 ...

Investment Rating - The report maintains an "Overweight" rating for the public utility sector and the power generation sector [2]. Core Viewpoints - The report argues that the core logic determining the valuation of power stocks has changed in the new energy era, with expectations of a rebound in electricity prices and stock valuations as coal prices stabilize [4][6]. - It highlights that the most challenging phase for electricity supply and demand in China has passed, with expectations of a recovery in demand starting in 2026 [4][7]. - The report emphasizes that the valuation gap between U.S. and Chinese power stocks has widened significantly, with U.S. power stocks trading at 2-4 times the price-to-book (PB) ratio of their Chinese counterparts [4][6][7]. Summary by Sections Investment Recommendations - The report recommends several undervalued power operators, including Huaneng International, Guodian Power, and China Power [3][8]. - It suggests that the capacity price increase in 2026 will benefit thermal power, while the stabilization of energy prices will favor nuclear, green, and hydropower [8]. Market Dynamics - The report notes that both China and the U.S. are experiencing similar electricity shortages due to a slowdown in the growth of base-load power sources, with structural demand exceeding expectations potentially leading to supply crises [5][26]. - It discusses the significant differences in electricity pricing structures between the two countries, with U.S. electricity prices being significantly higher due to various systemic costs [56][58]. Price Trends and Projections - The report predicts that by 2026, the industrial electricity prices in China will be significantly lower than those in the U.S., enhancing the competitiveness of Chinese manufacturing [6][11]. - It highlights that the electricity price gap between the two countries is expected to continue to widen, benefiting China's manufacturing sector [6][8]. Supply and Demand Outlook - The report indicates that the most severe supply-demand imbalance in China has passed, with expectations of a recovery in electricity demand driven by increased manufacturing investment [7][8]. - It also notes that the U.S. is facing a similar situation, with a projected decline in gas-fired electricity generation and a potential increase in coal-fired generation [5][30].

Group 1 - Northeast Securities expects a net profit of 1.477 billion yuan in 2025, a year-on-year increase of 69.06% [1] - Gansu Energy anticipates a net profit of 1.95 billion to 2.1 billion yuan in 2025, representing a year-on-year growth of 18.6% to 27.72% [2] - Ningbo Bank reports a projected net profit of 29.333 billion yuan in 2025, with an 8.13% year-on-year increase [3] Group 2 - Qianyuan Power forecasts a net profit of 567 million to 633 million yuan in 2025, indicating a year-on-year growth of 160% to 190% [5] - Batian Co. expects a net profit of 890 million to 980 million yuan in 2025, reflecting a year-on-year increase of 117.53% to 139.53% [6] - Tongfu Microelectronics anticipates a net profit of 1.1 billion to 1.35 billion yuan in 2025, with a year-on-year growth of 62.34% to 99.24% [7] Group 3 - Zhongyuan Nepe expects a net profit of 368 million to 428 million yuan in 2025, representing a year-on-year increase of 80.47% to 109.9% [8] - Huajin Co. predicts a net loss of 1.6 billion to 1.9 billion yuan in 2025, compared to a loss of 2.795 billion yuan in the previous year [9] - Xinghua Co. anticipates a net loss of 420 million to 560 million yuan in 2025, up from a loss of 380 million yuan in the previous year [4] Group 4 - Huayuan Holdings expects a net profit of 107 million to 118 million yuan in 2025, a year-on-year increase of 50.98% to 66.82% [12] - Taishan Petroleum forecasts a net profit of 130 million to 165 million yuan in 2025, indicating a year-on-year growth of 30.88% to 66.11% [13] - Jiuqi Software anticipates a net profit of 40 million to 60 million yuan in 2025, recovering from a loss of 156 million yuan in the previous year [21] Group 5 - Jin Fang Energy expects a net profit of 109 million to 143 million yuan in 2025, reflecting a year-on-year increase of 123.97% to 193.7% [16] - He Sheng New Materials anticipates a net profit of 152 million to 171 million yuan in 2025, representing a year-on-year growth of 55% to 75% [24] - Yuedong Microelectronics predicts a net loss of 340 million to 425 million yuan in 2025 [14] Group 6 - Aibo Medical plans to acquire at least 51% of Demai Medical, with an estimated valuation of the target company not exceeding 1 billion yuan [26] - Zhaoshang Shipping intends to build four 3000TEU container ships with a total investment of no more than 1.324 billion yuan [18] - Zhongtung High-tech's subsidiary has confirmed an increase in mineral resources, adding significant quantities of tungsten and other metals [27]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000600 证券简称：建投能源 公告编号：2026-05 证券代码：149516 证券简称：21建能01 证券代码：149743 证券简称：21建能02 河北建投能源投资股份有限公司 关于向特定对象发行股票的审核问询函回复（修订稿）及募集说明书等申请文件更新的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 河北建投能源投资股份有限公司（以下简称"公司"）于2025年11月13日收到深圳证券交易所（以下简 称"深交所"）出具的《关于河北建投能源投资股份有限公司申请向特定对象发行股票的审核问询函》 （审核函〔2025〕120053号）（以下简称《审核问询函》）。公司收到《审核问询函》后，会同相关中 介机构对《审核问询函》所列问题进行逐项回复和说明，同时对募集说明书等申请文件进行补充和更 新，并根据相关要求对《审核问询函》相关问题的回复予以披露，具体内容详见公司于2025年12月2日 在巨潮资讯网（http://www.cninfo.com.cn）披露的相关公告文件。 近日，根据深交所进一步审 ...

Group 1: Earnings Forecasts - Huabang Health expects a net profit of 660 million to 730 million yuan for 2025, recovering from a loss of 299 million yuan in the previous year, driven by improvements in its agricultural chemical materials sector and steady growth in its pharmaceutical and tourism segments [2] - Kangda New Materials anticipates a net profit of 125 million to 135 million yuan for 2025, compared to a loss of 246 million yuan last year, primarily due to significant sales growth in adhesive and specialty resin products, particularly in the wind power sector [2] - Longxin Technology forecasts a net profit of 100 million to 150 million yuan for 2025, recovering from a loss of 250 million yuan, with improvements in its energy digitalization business and reduced losses in its new energy sector [3] - Hualu Bio expects a net profit of 100 million to 130 million yuan for 2025, recovering from a loss of 47.57 million yuan, attributed to increases in both sales price and volume [3] - Jiuxi Software predicts a net profit of 40 million to 60 million yuan for 2025, recovering from a loss of 156 million yuan, supported by AI technology enhancements and market expansion strategies [3] Group 2: Major Corporate Developments - Liou Co. has completed its stock suspension review and will resume trading on January 21, 2026, confirming that its business operations remain normal and no significant undisclosed matters exist [4] - Hikvision reported total revenue of 92.518 billion yuan for 2025, a slight increase of 0.02%, with a net profit of 14.188 billion yuan, up 18.46%, driven by strategic adjustments and improved cash flow management [6] - JianTou Energy expects a net profit of approximately 1.877 billion yuan for 2025, a significant increase of about 253.38% from the previous year, due to optimized coal resource allocation and cost management [6] Group 3: Investment and Mergers - Aibo Medical plans to acquire at least 51% of Demai Medical to gain control, aiming to leverage its R&D advantages in the sports health sector [19] - Yifan Transmission intends to purchase 87.07% of Beijing Helishi Motor Technology Co., which will become a subsidiary upon successful completion of the transaction [16] - Guangdong Hongtu plans to invest up to 95 million yuan to establish a subsidiary in Thailand for automotive parts production and sales [20] Group 4: Stock Performance and Changes - Huicheng Environmental's major shareholder plans to increase their stake in the company by investing between 25 million and 50 million yuan within six months [22] - Liou Co. will resume trading after completing its stock suspension review, indicating stability in its operations [24] - Kailong High-Tech and Debang Co. have been suspended from trading, indicating potential issues or developments requiring further clarification [25]